Efficacy of novel transcatheter arterial therapy for hepatocellular carcinoma

肝動脈塞栓療法(TACE)は,肝細胞癌の代表的な治療法のひとつであり,有用性については認知されている.一方,手技上TACE不可能な症例には肝動脈化学療法(Lip-TAI)が汎用されるが,局所コントロールが不良との指摘もある.われわれは,新たな肝動脈カテーテル療法(Lip+DSM-TAI)を考案したので,その有用性について紹介する.

Transcatheter arterial chemoembolization (TACE) has become one of the most popular for hepatocellular carcinoma (HCC) patients. TACE has been reported to be a useful treatment. On the other hand, transcatheter arterial infusion chemotherapy using an emulsion of iodized oil (lipiodol) and an anticancer agent (Lip-TAI) (without gelatin sponge particle) has usually been performed for HCC patients in whom the catheter could not be inserted in the targeted segment or a feeding artery was not detected in the tumor. However, it has been reported that the effect of Lip-TAI was lower than that of TACE in the local tumor control. We designed a novel transcatheter arterial infusion chemotherapy using lipiodol and degradable starch microspheres［Lip+DSM-TAI］for HCC patients. We induct the efficacy of this novel therapy.

肝細胞癌

肝動脈カテーテル療法

塞栓療法

リピオドール

微小デンプン球